Hege O. Ohnstad, Russell Castro, Jinchang Sun, Karen-Marie Heintz, Lyubomir T. Vassilev, Bodil Bjerkehagen, Stine H. Kresse, Leonardo A. Meza-Zepeda and Ola Myklebost Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma Cancer 119
Version of Record online: 16 NOV 2012 | DOI: 10.1002/cncr.27837
In a large collection of sarcomas, patients with TP53 wild-type tumors had improved survival and response to chemotherapy, in particular with the apoptosis-prone variant R72. MDM2 overexpression on a TP53 wild-type background, predicted good response to MDM2 antagonists, irrespective of R72P or SNP309 status.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field